A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
AstraZeneca
AbbVie
Trishula Therapeutics, Inc.
NuCana plc
Eli Lilly and Company
UNICANCER
GlaxoSmithKline
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Sanofi
Proton Collaborative Group
Astellas Pharma Inc
Synta Pharmaceuticals Corp.
GlaxoSmithKline
Seagen Inc.
Case Comprehensive Cancer Center
Cell Genesys
Cell Genesys